Clinical Trial

A clinical trial is a prospective research study that assigns human participants to one or more health related interventions to evaluate their effects on health outcomes. Clinical trials follow predefined protocols specifying the study design, eligibility criteria, interventions, outcome measures, and statistical analysis plan. They require ethical approval and are typically registered in public databases such as ClinicalTrials.gov or the ISRCTN registry.

Clinical trials are the primary mechanism for establishing whether medical interventions are safe and effective. They provide the evidence base for drug approval, device clearance, and clinical practice guidelines. Medicines regulators, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), assess clinical trial data before new medicines can be authorized for marketing. For patients, clinical trials represent both an opportunity to access promising new treatments and a commitment to rigorous evaluation of those treatments. For the research community, randomized clinical trials are the gold standard for causal inference in medicine, providing the strongest evidence for treatment effects when properly designed and conducted. The results of clinical trials influence billions of dollars in healthcare expenditure and affect the health outcomes of millions of patients.

Clinical trials progress through a series of phases, each with distinct objectives. Phase I trials are small studies (typically 20 to 80 participants) that assess the safety, dosing, and pharmacokinetics of a new intervention in healthy volunteers or patients. Phase II trials are medium sized studies (typically 100 to 300 participants) that evaluate the intervention's efficacy and further assess safety in patients with the target condition. Phase III trials are large scale studies (hundreds to thousands of participants) that confirm efficacy, monitor side effects, and compare the new intervention with the current standard of care or, where appropriate, with placebo. Phase IV trials are post marketing studies that evaluate long term safety, effectiveness in broader populations, and optimal use in clinical practice.

The design of a clinical trial is specified in a protocol, which details the study objectives, participant eligibility criteria, intervention procedures, outcome measures, randomization and blinding methods, sample size justification, data collection procedures, and statistical analysis plan. The protocol is reviewed and approved by institutional review boards or ethics committees before enrollment begins.

Randomization and blinding are key design features that minimize bias. Randomization makes treatment groups comparable at baseline, in both known and unknown factors, apart from chance differences, while blinding reduces the risk that knowledge of treatment assignments influences behavior and outcome assessment. Intention to treat analysis, which analyzes all randomized participants in their assigned groups regardless of adherence or withdrawal, preserves the benefits of randomization.

Registration in a public database is now widely required, though the timing rules differ. Journals that follow the International Committee of Medical Journal Editors (ICMJE) recommendations require registration at or before the time of first patient consent for enrollment as a condition of consideration for publication; the Declaration of Helsinki requires registration before recruitment of the first participant; and in the US, FDAAA 801 requires applicable clinical trials to be registered on ClinicalTrials.gov no later than 21 calendar days after the first participant is enrolled. Registration promotes transparency by making the trial's existence, design, and primary outcomes publicly available, reducing the risk of selective outcome reporting and publication bias.

Clinical trials are the appropriate design for evaluating the efficacy and safety of therapeutic interventions in humans. In the US, for example, the FDA generally requires them for approval of new drugs, biologics, and high risk medical devices. They are also used to compare existing treatments, evaluate diagnostic strategies, and test preventive interventions such as vaccines. Clinical trials are not appropriate when randomization is unethical (e.g., exposing participants to known harmful agents), when the condition is too rare to recruit sufficient participants, or when the research question can be adequately addressed with observational data.

A common error is conducting a trial without adequate sample size to detect clinically meaningful effects, resulting in an underpowered study that wastes resources and exposes participants to risk without generating actionable evidence. Another mistake is failing to pre register the trial and specify the primary outcome before enrollment, which enables selective outcome reporting.

Researchers sometimes also deviate from the pre specified analysis plan without documenting and justifying the changes, undermining the credibility of the results. Poor adherence to randomization and blinding procedures can introduce bias even in well designed trials. Finally, reporting trial results selectively (publishing positive results while suppressing negative or null findings) contributes to publication bias and distorts the evidence base for clinical decision making.

A pharmaceutical company conducts a Phase III, double blind, placebo controlled, multicenter clinical trial to evaluate a new monoclonal antibody for moderate to severe atopic dermatitis. The trial enrolls 1,200 patients across 80 sites in 12 countries. Participants are randomized 2:1 to the active drug or placebo, stratified by disease severity and geographic region. The primary endpoint is the proportion of patients achieving at least 75% improvement on the Eczema Area and Severity Index (EASI 75) at week 16. The trial finds that 58% of patients in the active group achieve EASI 75, compared to 17% in the placebo group (p < 0.0001, NNT = 3: 1 ÷ 0.41 = 2.44, rounded up). Based on these results and the safety data, the manufacturer submits a regulatory application for marketing approval.